NO20090531L - Fremstilling av ultraren EPA og polare lipider fra hovedsakelig heterotrofe kulturer - Google Patents

Fremstilling av ultraren EPA og polare lipider fra hovedsakelig heterotrofe kulturer

Info

Publication number
NO20090531L
NO20090531L NO20090531A NO20090531A NO20090531L NO 20090531 L NO20090531 L NO 20090531L NO 20090531 A NO20090531 A NO 20090531A NO 20090531 A NO20090531 A NO 20090531A NO 20090531 L NO20090531 L NO 20090531L
Authority
NO
Norway
Prior art keywords
epa
polar lipids
ultra
preparation
rich
Prior art date
Application number
NO20090531A
Other languages
English (en)
Inventor
Karl Thomas Geiringer
Hywel David Griffiths
Original Assignee
Photonz Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photonz Corp Ltd filed Critical Photonz Corp Ltd
Publication of NO20090531L publication Critical patent/NO20090531L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6458—Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)

Abstract

Det er beskrevet eikosapentaensyre (EPA) sammensetninger og EPA-rike polare lipider for profylaktiske eller terapeutiske applikasjoner. Fremstilling fra visse dyrkede mikroorganismer (så som Nitzschia laevis) fremmer syntese av EP A, som inkluderer polare lipider som inkluderer EPA. De EPA-rike polare lipider i seg selv kan anvendes som polare forbindelser. EPA kan selektivt hydrolyseres fra spesielle posisjoner i isolerte polare lipider ved lipaseaktivitet, deretter eventuelt ytterligere renses. Prosessen forbigår avhengigheten av svinnende fiskelagre og på fysikalsk-kjemiske prosesser som ikke adekvat kan separere ønskelige n-3 HUFA' er fra uønskede produkter så som DUA også funnet i fiskeolje og dyrkede organismer.
NO20090531A 2006-07-05 2009-02-03 Fremstilling av ultraren EPA og polare lipider fra hovedsakelig heterotrofe kulturer NO20090531L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ54833906 2006-07-05
PCT/NZ2007/000172 WO2008004900A1 (en) 2006-07-05 2007-07-05 Production of ultrapure epa and polar lipids from largely heterotrophic culture

Publications (1)

Publication Number Publication Date
NO20090531L true NO20090531L (no) 2009-02-03

Family

ID=38894787

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090531A NO20090531L (no) 2006-07-05 2009-02-03 Fremstilling av ultraren EPA og polare lipider fra hovedsakelig heterotrofe kulturer

Country Status (8)

Country Link
US (3) US8877465B2 (no)
EP (1) EP2044208A4 (no)
JP (1) JP5658876B2 (no)
AU (1) AU2007270135B9 (no)
CA (1) CA2656311C (no)
NO (1) NO20090531L (no)
NZ (1) NZ573719A (no)
WO (1) WO2008004900A1 (no)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295594B1 (en) 2000-01-19 2018-04-04 DSM IP Assets B.V. Solventless extraction process
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
NZ594395A (en) 2009-02-10 2014-01-31 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SI3318255T1 (sl) 2009-06-15 2021-07-30 Amarin Pharmaceuticals Ireland Limited Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom
US8399226B2 (en) 2009-06-16 2013-03-19 E I Du Pont De Nemours And Company High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica
CN101613724B (zh) * 2009-07-28 2011-04-06 嘉吉烯王生物工程(湖北)有限公司 重复利用高山被孢霉菌粕制备花生四烯酸的方法
KR101856055B1 (ko) * 2009-09-18 2018-05-09 파이코일 바이오테크놀로지 인터내셔널, 아이엔씨. 조절되는 조명을 사용하는 미세조류 발효
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
ES2862980T3 (es) * 2009-12-30 2021-10-08 Basf Pharma Callanish Ltd Composiciones de ácido graso poliinsaturado obtenibles mediante un proceso de separación cromatográfica en lecho móvil simulado
AU2013204090B2 (en) * 2009-12-30 2015-01-29 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
DK2526197T3 (en) 2010-01-19 2018-10-01 Dsm Ip Assets Bv MICRO; PRODUCING EICOSAPENTAIC ACID AND DOCOSAHEXAENIC ACID, FATIC ACID COMPOSITIONS, AND METHODS FOR PREPARING AND USING THEREOF
KR20130026428A (ko) * 2010-03-04 2013-03-13 아마린 파마, 인크. 심혈관 질환을 치료 및/또는 예방하기 위한 조성물 및 방법
EP2576801B1 (en) 2010-06-01 2019-10-02 DSM IP Assets B.V. Extraction of lipid from cells and products therefrom
EP3527665A1 (en) 2010-06-09 2019-08-21 Fermentalg Compositions comprising eicosapentaenoic acid suitable for high purification
FR2964667B1 (fr) * 2010-09-15 2014-08-22 Fermentalg Procede de culture d'algues unicellulaires mixotrophes en presence d'un apport lumineux discontinu sous forme de flashs
AU2011312987A1 (en) * 2010-10-06 2013-05-02 Photonz Corporation Limited Heterotrophic microbial production of xanthophyll pigments
US10479969B2 (en) 2010-10-11 2019-11-19 Phycoil Biotechnology International. Inc. Utilization of wastewater for microalgal cultivation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) * 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012103685A1 (en) * 2011-02-01 2012-08-09 Nippon Suisan Kaisha, Ltd. Sexual function improving agent
CN103327982A (zh) * 2011-02-01 2013-09-25 日本水产株式会社 性功能改善剂
AU2012214260A1 (en) * 2011-02-11 2013-07-25 E. I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
CN105410925A (zh) 2011-07-21 2016-03-23 帝斯曼知识产权资产管理有限公司 脂肪酸组合物
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
FR2988098A1 (fr) * 2012-03-16 2013-09-20 Fermentalg Production d'acide docosahexaenoique en mode mixotrophe par nitzschia
US9719115B2 (en) 2012-05-10 2017-08-01 Kyoto University Method for producing oxo fatty acid and rare fatty acid
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
MX2020013922A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2014074770A2 (en) 2012-11-09 2014-05-15 Heliae Development, Llc Balanced mixotrophy methods
WO2014074772A1 (en) 2012-11-09 2014-05-15 Heliae Development, Llc Mixotrophic, phototrophic, and heterotrophic combination methods and systems
JP2016501249A (ja) * 2012-12-06 2016-01-18 マティナス バイオファーマ インコーポレイテッド ドコサペンタエン酸を含む組成物の投与
CA2894709C (en) * 2012-12-24 2022-08-09 Qualitas Health, Ltd. Eicosapentaenoic acid (epa) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9445619B2 (en) * 2013-03-15 2016-09-20 Aurora Algae, Inc. Compositions and methods for utilization of algal compounds
WO2014146098A1 (en) * 2013-03-15 2014-09-18 Aurora Algae, Inc. Compositions of crude algal oil
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
EP3027732B1 (en) 2013-08-01 2020-07-22 Fermentalg Methods for the production of diatom biomass
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
NL2011472C2 (en) 2013-09-19 2015-03-23 Univ Delft Tech Storage compound production by phototrophic diatoms.
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3118186B1 (fr) 2013-12-11 2022-02-09 Novasep Process Installation chromatographique de production d acides gras polyinsatures
WO2015095690A2 (en) 2013-12-20 2015-06-25 Dsm Ip Assets B.V. Processes for obtaining microbial oil from microbial cells
MX2016008223A (es) 2013-12-20 2016-11-28 Dsm Ip Assets Bv Procedimiento para la obtención de aceite microbiano a partir de células microbianas.
BR112016014516B1 (pt) 2013-12-20 2022-02-22 Dsm Ip Assets B.V Processos para obter óleo microbiano de células microbianas e óleo
PL3082793T3 (pl) 2013-12-20 2020-10-05 Dsm Ip Assets B.V. Sposoby otrzymywania oleju drobnoustrojowego z komórek drobnoustrojowych
US10975031B2 (en) 2014-01-07 2021-04-13 Novasep Process Method for purifying aromatic amino acids
JP2015146788A (ja) * 2014-02-07 2015-08-20 三菱マテリアル株式会社 藻類培養方法及び藻類培養装置
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3469085B1 (en) * 2016-06-08 2021-07-28 Swedish Algae Factory AB Frustules extracted from benthic pennate diatoms harvested from an industrial biofilm process
CN105912054B (zh) * 2016-06-24 2018-11-20 国网山东省电力公司聊城供电公司 一种油色谱在线装置柜的温控***及其工作方法与应用
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
CN107099379A (zh) * 2017-06-09 2017-08-29 云南中烟工业有限责任公司 一种用于电子烟的津巴布韦烟草净油
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FR3085962B1 (fr) 2018-09-14 2021-06-18 Fermentalg Procede d'extracton d'une huile riche en pufa
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
JP7395144B2 (ja) * 2019-04-05 2023-12-11 三菱重工機械システム株式会社 微細藻培養方法および微細藻培養装置
WO2021211990A1 (en) * 2020-04-17 2021-10-21 Wake Forest University Lipid compositions and methods of preparation thereof
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1969433U (de) * 1967-04-14 1967-09-28 Bernhard Dipl Ing Winkler Beschilderungselement.
JPS5946225A (ja) 1982-09-09 1984-03-15 Kogyo Kaihatsu Kenkyusho 抗動脈硬化剤の製造方法
JPS6163624A (ja) * 1984-09-05 1986-04-01 Nisshin Oil Mills Ltd:The エイコサペンタエン酸含量の高い糖脂質の製造法
JPH0297373A (ja) * 1988-09-30 1990-04-09 Koujiyouen:Kk ビールの製造方法
JPH0297393A (ja) 1988-10-03 1990-04-09 Sagami Chem Res Center エイコサペンタエン酸を含むリン脂質組成物の海洋微生物による製造法
JPH02145191A (ja) * 1988-11-29 1990-06-04 Tosoh Corp 海洋性微生物からの高度不飽和脂肪酸の分離方法
US5244921A (en) 1990-03-21 1993-09-14 Martek Corporation Eicosapentaenoic acids and methods for their production
AU6821294A (en) * 1993-04-30 1994-11-21 Rodner R. Winget Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
GB9404483D0 (en) * 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
DE19629433A1 (de) * 1996-07-22 1998-01-29 Hoechst Ag Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
JP3836231B2 (ja) * 1997-10-17 2006-10-25 日本化学飼料株式会社 ホタテガイ中腸腺から得られる高度不飽和脂肪酸含有油及びその製造方法
AU2004235641B2 (en) 1999-01-27 2006-09-14 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
CA2273570A1 (en) * 1999-05-31 2000-11-30 Jfs Envirohealth Ltd. Concentration and purification of polyunsaturated fatty acid esters by distillation-enzymatic transesterification coupling
JP4170542B2 (ja) * 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
EP2295594B1 (en) * 2000-01-19 2018-04-04 DSM IP Assets B.V. Solventless extraction process
MX281182B (es) * 2001-05-14 2010-11-22 Martek Biosciences Boulder Corp Produccion y uso de una fraccion rica en lipidos polares, que contienen acidos grasos altamente insaturados omega-3 y/u omega-6, procedentes de microbios, de semillas de plantas y de organismos marinos geneticamente modificados.
EP2966172B1 (en) 2002-10-11 2018-02-21 Nippon Suisan Kaisha, Ltd. Process for producing microbial fat or oil having lowered unsaponifiable matter content and said fat or oil
GB0301701D0 (en) * 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
US8557551B2 (en) * 2004-09-10 2013-10-15 Dsm Ip Assets B.V. Compositions and methods for making and modifying oils
US20100021555A1 (en) 2004-10-15 2010-01-28 Karl Geiringer Compositions containing high omega-3 and low saturated fatty acid levels
US20070225370A1 (en) * 2006-03-21 2007-09-27 Joar Opheim Nutritional Compositions and Methods

Also Published As

Publication number Publication date
AU2007270135B2 (en) 2013-06-20
AU2007270135B9 (en) 2013-06-27
CA2656311C (en) 2016-06-21
JP2009542205A (ja) 2009-12-03
US20170326090A1 (en) 2017-11-16
AU2007270135A1 (en) 2008-01-10
WO2008004900A1 (en) 2008-01-10
CA2656311A1 (en) 2008-01-10
JP5658876B2 (ja) 2015-01-28
EP2044208A4 (en) 2012-02-22
EP2044208A1 (en) 2009-04-08
NZ573719A (en) 2011-08-26
US20150057353A1 (en) 2015-02-26
US8877465B2 (en) 2014-11-04
US20100069492A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
NO20090531L (no) Fremstilling av ultraren EPA og polare lipider fra hovedsakelig heterotrofe kulturer
EP3623465A3 (en) Production of fatty acids and derivatives thereof
EP2194119A3 (en) Production of fatty acids and derivatives thereof
de Jesus Raposo et al. Health applications of bioactive compounds from marine microalgae
de Morais et al. Biologically active metabolites synthesized by microalgae
EP3369807A3 (en) Enhanced production of fatty acid derivatives
NO20090692L (no) Farmasoytiske og kostholdsprodukter som omfatter vitamin K2
Sayegh et al. Production of polyunsaturated single cell oils possessing antimicrobial and anticancer properties
WO2007069078A3 (en) Eukaryotic microorganisms for producing lipids and antioxidants
WO2006046943A8 (en) Methods for producing lipids by liberation from biomass
WO2006124598A3 (en) Biomass hydrolysate and uses and production thereof
CL2013003791A1 (es) Proceso para fabricar una biomasa algal que comprende al menos 67% de grasa total que incluye cultivar un alga bajo condiciones de cultivo suficientes para proporcionar una biomasa algal que comprende 67% o mas de grasa total; biomasa; composicion de lipidos; y producto alimenticio.
MX2017010710A (es) Composición terapeútica y profiláctica producida por microbiota.
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
EP1707055A3 (en) Enhanced production of lipids containing polyenoic fatty acids by very high density cultures of eukaryotic microbes in fermentors
WO2009134791A3 (en) Processing biomass
UA90719C2 (ru) Способ изготовления молока или молочных продуктов с высоким содержанием мелатонина
NZ596228A (en) Compositions and methods for the treatment of inflammation
Veronesiv et al. Pre-treated digestate as culture media for producing algal biomass
MX2010005736A (es) Purificacion de materiales grasos tales como aceite.
EP2019133A8 (en) MICROORGANISM CAPABLE OF PRODUCING gamma-L-PGA, METHOD FOR PRODUCTION OF gamma-L-PGA USING THE MICROORGANISM, CROSSLINKED PRODUCT, AND AGENT FOR EXTERNAL APPLICATION TO THE SKIN
Shanthi et al. Effects of L-amino acids as organic nitrogen source on the growth rate, biochemical composition and polyphenol content of Spirulina platensis
EP4295901A3 (en) Fish protein hydrolysate powder and a composition comprising said powder for use as a medicament
UA87822C2 (ru) Производные нафтилена как ингибиторы цитохрома p450
WO2010042478A3 (en) Modular experimental platform for microorganism physiology and scale-up studies

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application